New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue.
Chemotherapy resistance and related defects in apoptotic signaling are crucial for the high mortality of melanoma. Effective drugs are lacking, also due to the fact that apoptosis regulation in this tumor is essentially not understood. The cytosine analogue ferropoptoside (N69), which contains an iron carbonyl complex, resulted in strong induction of apoptosis in melanoma cells starting already after 2h, whereas cytotoxicity remained at a low level. Surprisingly, there was no indication for any caspase activation at early times, although cytochrome c was released from mitochondria. Indicative for new proapoptotic pathways was the production of reactive oxygen species (ROS) as an early effect, and the inhibition of apoptosis by the antioxidant vitamin E. Apoptosis was also blocked by exogenous Bcl-2 overexpression and by the pan-protease inhibitor zVAD. However, only zVAD also prevented ROS production, for which Bcl-2 remained without an effect. Thus, new proapoptotic pathways are described here for melanoma cells clearly related to ROS production. A cascade enclosing enhanced levels of intracellular iron, which lead to enhanced ROS production in a Fenton reaction, appears as suggestive. Whereas off-target effects of zVAD appear as upstream, Bcl-2 may exert its inhibitory activity downstream of ROS. New proapoptotic pathways are of particular interest for melanoma as they may open new options for targeting this highly therapy-refractory tumor.
Department of Dermatology and Allergy, Skin Cancer Center Charité, Charitéplatz 1, 10117 Berlin, Germany.
Jeannine C
JC
Franke
Michael
M
Plötz
Aram
A
Prokop
Christoph C
CC
Geilen
Hans-Günther
HG
Schmalz
Jürgen
J
Eberle
D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D020169:Caspases / Q000502:physiology*; D045744:Cell Line, Tumor; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016503:Drug Delivery Systems / Q000379:methods; D005296:Ferrous Compounds / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D017382:Reactive Oxygen Species / Q000378:metabolism* / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D005296:Ferrous Compounds; D017382:Reactive Oxygen Species; D003596:Cytosine; D020169:Caspases